James K. Sheffield

962 total citations
35 papers, 669 citations indexed

About

James K. Sheffield is a scholar working on Pathology and Forensic Medicine, Neurology and Oncology. According to data from OpenAlex, James K. Sheffield has authored 35 papers receiving a total of 669 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pathology and Forensic Medicine, 6 papers in Neurology and 6 papers in Oncology. Recurrent topics in James K. Sheffield's work include Multiple Sclerosis Research Studies (24 papers), Polyomavirus and related diseases (6 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (5 papers). James K. Sheffield is often cited by papers focused on Multiple Sclerosis Research Studies (24 papers), Polyomavirus and related diseases (6 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (5 papers). James K. Sheffield collaborates with scholars based in United States, Italy and Switzerland. James K. Sheffield's co-authors include Bruce Cree, Jeffrey A. Cohen, Ludwig Kappos, Douglas L. Arnold, Xavier Montalbán, Lawrence Steinman, Hans‐Peter Hartung, Gıancarlo Comı, Eva Havrdová and Krzysztof Selmaj and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and Neurology.

In The Last Decade

James K. Sheffield

30 papers receiving 652 citations

Peers

James K. Sheffield

PFM

NEURO

ONCOL

IMMUN

Tamara Castillo‐Triviño Spain

Brenda Huppke Germany

Undine Proschmann Germany

Tobias Moser Austria

Aurora Zanghì Italy

C. Smestad Norway

Jason P. Mendoza United States

Alessandro Marti Italy

Paola Valentino Italy

T. Arbizu Spain

Tamara Castillo‐Triviño Spain

James K. Sheffield

394 ×1.0

PFM

571 ×2.7

166 ×0.9

NEURO

119 ×1.1

ONCOL

183 ×1.9

IMMUN

Citations per year, relative to James K. Sheffield James K. Sheffield (= 1×) peers Tamara Castillo‐Triviño

Countries citing papers authored by James K. Sheffield

Since Specialization

Citations

This map shows the geographic impact of James K. Sheffield's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James K. Sheffield with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James K. Sheffield more than expected).

Fields of papers citing papers by James K. Sheffield

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James K. Sheffield. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James K. Sheffield. The network helps show where James K. Sheffield may publish in the future.

Co-authorship network of co-authors of James K. Sheffield

This figure shows the co-authorship network connecting the top 25 collaborators of James K. Sheffield. A scholar is included among the top collaborators of James K. Sheffield based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James K. Sheffield. James K. Sheffield is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Filippi, Massimo, Jeffrey A. Cohen, Hans‐Peter Hartung, et al.. (2024). Relapse-associated Worsening and Progression-independent Relapse Activity in Ozanimod-treated Participants with Relapsing Multiple Sclerosis from the RADIANCE and DAYBREAK Trials (P6-6.014). Neurology. 102(7_supplement_1).

Cree, Bruce, Amit Bar‐Or, Hans‐Peter Hartung, et al.. (2023). SARS‐CoV‐2 vaccination and infection in ozanimod‐treated participants with relapsing multiple sclerosis. Annals of Clinical and Translational Neurology. 10(10). 1725–1737. 3 indexed citations

Naismith, Robert T., Jeffrey A. Cohen, Amit Bar‐Or, et al.. (2023). Concurrent administration of serotonergic antidepressants and ozanimod in participants with relapsing multiple sclerosis from the open-label extension DAYBREAK trial. Multiple Sclerosis Journal. 30(2). 177–183. 3 indexed citations

DeLuca, John, Jeffrey A. Cohen, Bruce Cree, et al.. (2023). Effects of Ozanimod on Cognitive Processing Speed: Findings From the Phase 3 SUNBEAM and DAYBREAK Extension Trials (P6-3.001). Neurology. 100(17_supplement_2). 2 indexed citations

Kappos, Ludwig, Giacomo P. Comi, Krzysztof Selmaj, et al.. (2022). Evaluating No Evidence of Disease Activity in Patients With Relapsing Multiple Sclerosis: Post Hoc Analysis of the Phase 3 RADIANCE and Open-Label Extension Studies of Ozanimod (P7-4.012). Neurology. 98(18_supplement). 1 indexed citations

Cree, Bruce, Krzysztof Selmaj, Lawrence Steinman, et al.. (2022). Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial. Multiple Sclerosis Journal. 28(12). 1944–1962. 30 indexed citations

Siegmund, Britta, Gil Melmed, Peter M. Irving, et al.. (2022). P402 Incidence and outcomes of herpes zoster in the ozanimod phase, 3 ulcerative colitis and relapsing multiple sclerosis clinical program. Journal of Crohn s and Colitis. 16(Supplement_1). i395–i396. 4 indexed citations

Selmaj, Krzysztof, Jeffrey A. Cohen, Gıancarlo Comı, et al.. (2021). Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program. Multiple Sclerosis and Related Disorders. 51. 102844–102844. 26 indexed citations

Cross, Raymond K., Jonathan Calkwood, Ashwini Pai, et al.. (2021). P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis. The American Journal of Gastroenterology. 116(1). S9–S10. 6 indexed citations

10.

Colombel, Jean‐Frédéric, Michael Silver, James K. Sheffield, et al.. (2021). S745 Safety of Concurrent Administration of Ozanimod and Serotonergic Antidepressants in Patients With Ulcerative Colitis. The American Journal of Gastroenterology. 116(1). S343–S343. 1 indexed citations

11.

Harris, Sarah, Giacomo P. Comi, Bruce Cree, et al.. (2021). 067 Neurofilament light chain concentration predicts risk of relapse in participants with relapsing multiple sclerosis in phase 3 ozanimod trials. SHILAP Revista de lepidopterología. A24.2–A25. 2 indexed citations

12.

DeLuca, John, Sven Schippling, Xavier Montalbán, et al.. (2020). Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS. Multiple Sclerosis and Related Disorders. 48. 102673–102673. 27 indexed citations

13.

Steinman, Lawrence, Giancarlo Comi, Bruce Cree, et al.. (2019). Ozanimod Efficacy in Relapsing Multiple Sclerosis Supported by Open-Label Long-Term Extension of Two Phase 3 Trials (P3.2-036). Neurology. 92(15_supplement).

14.

Cohen, Jeffrey A., Gıancarlo Comı, Krzysztof Selmaj, et al.. (2019). Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. The Lancet Neurology. 18(11). 1021–1033. 197 indexed citations

15.

Comı, Gıancarlo, Ludwig Kappos, Krzysztof Selmaj, et al.. (2019). Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. The Lancet Neurology. 18(11). 1009–1020. 205 indexed citations

16.

Harris, Sarah, Gıancarlo Comı, Bruce Cree, et al.. (2019). Neurofilament Light Chains as a Marker of Concurrent and Future Active Disease in Relapsing Multiple Sclerosis: An Analysis of Baseline Data From the Phase 3 Ozanimod Clinical Trials (S56.006). Neurology. 92(15_supplement). 2 indexed citations

17.

Cohen, Jeffrey A., Giancarlo Comi, Krzysztof Selmaj, et al.. (2018). Clinical and Magnetic Resonance Imaging Results From RADIANCE Part B, a Multicenter, Randomized, Double-Blind, Phase 3 Trial of Ozanimod Versus Intramuscular Interferon β-1a in Relapsing Multiple Sclerosis (RMS) (P3.410). Neurology. 90(15_supplement). 3 indexed citations

18.

Cree, Bruce, Amit Bar‐Or, Giancarlo Comi, et al.. (2018). Safety of Ozanimod Versus Interferon β-1a in Two Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Controlled, Double-Dummy Phase 3 Studies in Relapsing Multiple Sclerosis (SUNBEAM and RADIANCE Part B) (S36.006). Neurology. 90(15_supplement). 2 indexed citations

19.

Sheffield, James K., et al.. (2009). Motor overflow and mirror dystonia. Parkinsonism & Related Disorders. 15(10). 758–761. 37 indexed citations

20.

Sheffield, James K. & Joseph Jankovic. (2007). Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson’s disease. Expert Review of Neurotherapeutics. 7(6). 637–647. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact